Header Logo

Connection

ALAN SWANN to Treatment Outcome

Back to Details
This is a "connection" page, showing publications ALAN SWANN has written about Treatment Outcome.
ALAN SWANN
Connection Strength
0.432
Treatment Outcome
  1. Lurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis. CNS Spectr. 2017 Apr; 22(2):228-235.
    View in: PubMed
    Score: 0.042
  2. Mixed features: evolution of the concept, past and current definitions, and future prospects. CNS Spectr. 2017 Apr; 22(2):161-169.
    View in: PubMed
    Score: 0.042
  3. Bipolar mixed states: an international society for bipolar disorders task force report of symptom structure, course of illness, and diagnosis. Am J Psychiatry. 2013 Jan; 170(1):31-42.
    View in: PubMed
    Score: 0.032
  4. Approaches to preventing relapse in bipolar disorder: addressing nonadherence and prodromal symptoms. J Clin Psychiatry. 2010 Dec; 71(12):e35.
    View in: PubMed
    Score: 0.027
  5. What is bipolar disorder? Am J Psychiatry. 2006 Feb; 163(2):177-9.
    View in: PubMed
    Score: 0.020
  6. Psychosis in mania: specificity of its role in severity and treatment response. J Clin Psychiatry. 2004 Jun; 65(6):825-9.
    View in: PubMed
    Score: 0.017
  7. Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial. Neuropsychopharmacology. 2023 10; 48(11):1586-1593.
    View in: PubMed
    Score: 0.016
  8. Replication of distinct trajectories of antidepressant response to intravenous ketamine. J Affect Disord. 2023 01 15; 321:140-146.
    View in: PubMed
    Score: 0.016
  9. Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial. Neuropsychopharmacology. 2022 04; 47(5):1088-1095.
    View in: PubMed
    Score: 0.015
  10. Neurophysiological and clinical effects of the NMDA receptor antagonist lanicemine (BHV-5500) in PTSD: A randomized, double-blind, placebo-controlled trial. Depress Anxiety. 2021 11; 38(11):1108-1119.
    View in: PubMed
    Score: 0.014
  11. Distinct trajectories of antidepressant response to intravenous ketamine. J Affect Disord. 2021 05 01; 286:320-329.
    View in: PubMed
    Score: 0.014
  12. ECT in mixed affective states: a case series. J ECT. 2000 Jun; 16(2):183-8.
    View in: PubMed
    Score: 0.013
  13. Mania: differential effects of previous depressive and manic episodes on response to treatment. Acta Psychiatr Scand. 2000 Jun; 101(6):444-51.
    View in: PubMed
    Score: 0.013
  14. Mania: gender, transmitter function, and response to treatment. Psychiatry Res. 1999 Oct 18; 88(1):55-61.
    View in: PubMed
    Score: 0.013
  15. "A two-illness model of bipolar disorder"--RT Joffe, LT Young, and GM MacQueen: a commentary. Bipolar Disord. 1999 Sep; 1(1):38-41.
    View in: PubMed
    Score: 0.013
  16. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am J Psychiatry. 1999 Aug; 156(8):1264-6.
    View in: PubMed
    Score: 0.012
  17. Depression during mania. Treatment response to lithium or divalproex. Arch Gen Psychiatry. 1997 Jan; 54(1):37-42.
    View in: PubMed
    Score: 0.010
  18. Psychometric properties of the MSPSS and NOS in psychiatric outpatients. J Clin Psychol. 1995 Sep; 51(5):593-602.
    View in: PubMed
    Score: 0.009
  19. Mixed or dysphoric manic states: psychopathology and treatment. J Clin Psychiatry. 1995; 56 Suppl 3:6-10.
    View in: PubMed
    Score: 0.009
  20. A randomized, double-blind, placebo-controlled trial of quetiapine in patients with bipolar disorder, mixed or depressed phase, and alcohol dependence. Alcohol Clin Exp Res. 2014 Jul; 38(7):2113-8.
    View in: PubMed
    Score: 0.009
  21. Depressive mania: response of residual depression to bupropion. Biol Psychiatry. 1994 Apr 01; 35(7):493-4.
    View in: PubMed
    Score: 0.009
  22. Baseline neurocognitive profiles differentiate abstainers and non-abstainers in a cocaine clinical trial. J Addict Dis. 2009 Jul; 28(3):250-7.
    View in: PubMed
    Score: 0.006
  23. A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry. 2006 Oct; 67(10):1501-10.
    View in: PubMed
    Score: 0.005
  24. Extended-release carbamazepine capsules as monotherapy in bipolar disorder : pooled results from two randomised, double-blind, placebo-controlled trials. CNS Drugs. 2006; 20(3):219-31.
    View in: PubMed
    Score: 0.005
  25. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry. 2005 Mar; 162(3):621-4.
    View in: PubMed
    Score: 0.005
  26. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2005 Mar; 66(3):323-30.
    View in: PubMed
    Score: 0.005
  27. A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. J Clin Psychiatry. 2004 Jan; 65(1):114-9.
    View in: PubMed
    Score: 0.004
  28. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology. 2003 Jul; 28(7):1374-82.
    View in: PubMed
    Score: 0.004
  29. Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. J Clin Psychiatry. 2003 Mar; 64(3):288-94.
    View in: PubMed
    Score: 0.004
  30. The impact of impulsivity on cocaine use and retention in treatment. J Subst Abuse Treat. 2001 Dec; 21(4):193-8.
    View in: PubMed
    Score: 0.004
  31. Texas Medication Algorithm Project: development and feasibility testing of a treatment algorithm for patients with bipolar disorder. J Clin Psychiatry. 2001 Jun; 62(6):439-47.
    View in: PubMed
    Score: 0.004
  32. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry. 2000 Nov; 61(11):841-50.
    View in: PubMed
    Score: 0.003
  33. Pharmacotherapy of depression and mixed states in bipolar disorder. J Affect Disord. 2000 Sep; 59 Suppl 1:S39-S56.
    View in: PubMed
    Score: 0.003
  34. The Brief Psychiatric Rating Scale as an acute inpatient outcome measurement tool: a pilot study. J Clin Psychiatry. 2000 Jun; 61(6):418-21.
    View in: PubMed
    Score: 0.003
  35. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry. 2000 May; 57(5):481-9.
    View in: PubMed
    Score: 0.003
  36. Effect size of efficacy measures comparing divalproex, lithium and placebo in acute mania. Depress Anxiety. 1997; 6(1):26-30.
    View in: PubMed
    Score: 0.003
  37. Relation of serum valproate concentration to response in mania. Am J Psychiatry. 1996 Jun; 153(6):765-70.
    View in: PubMed
    Score: 0.002
  38. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA. 1994 Mar 23-30; 271(12):918-24.
    View in: PubMed
    Score: 0.002
  39. Depressive mania associated with nonresponse to antimanic agents. Am J Psychiatry. 1993 Oct; 150(10):1548-51.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.